Two Phase III Trials Show Increase In PFS In Two Distinct Patient Populations
Phase III Trial In Recurrent Disease Shows Lower Risk of Progression or Death by 34%
Two Conflicting Studies Presented at ASCO 2013, FDA Called Upon To Sort Through The Data
Phase III Alimta Trial Fails To Extend Progression-Free Survival Without Grade 4 Adverse Events
Votrient Trial Meets PFS Endpoint In Epithelial Ovarian Cancer
Afinitor Extends PFS In Women With EGFR-2 Positive Disease
Analysis Reveals CAIX Subgroup Responsive to Rencarex Therapy
Inhibitor Reduces Spleen Size By 35 Percent or More in Phase III
CTEP-Approved Trials For the Month of June
FDA Approves Two Oral Drugs For Metastatic Melanoma
Trending Stories
- The story of daraxonrasib is the ultimate hero’s journey
A narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe - At Senate hearing, Brown’s El-Deiry and other witnesses say they were targeted for arguing that mRNA vaccine may be linked to cancer
- Pancreatic cancer finally starts to budge as daraxonrasib doubles overall survival
- Daraxonrasib’s success in treating pancreatic cancer is a reminder that clinical cancer researchers are heroes
- Pam Bondi diagnosed with thyroid cancer
- Political appointees to be inserted into all stages of making research funding awards if OMB rule becomes final
